The EU’s Global Gateway Strategy includes hundreds of sustainable and quality investment projects. Projects identified as flagships and included in the list are prominent examples of the progress and deliverables of Global Gateway.
The aim of this list of flagship projects is to showcase the priorities of the Union, its Member States, and our partners, and contribute to strengthening our strategic partnerships and the promotion of our joint interests.
The list of Global Gateway flagship projects for the year 2025 includes a total of 46 projects and set specific milestones for the implementation of the actions within the year.
Two projects of Greek interest were included in the 2025 list, following actions taken by the Hellenic Ministry of Foreign Affairs, an “Integrated Bauxite and Aluminium Project in Ghana” and a “Healthcare Investment in Egypt”.
The “Integrated Bauxite and Aluminium Project in Ghana” is being carried out with the participation of “Metlen Energy & Metals” and focuses on exploiting the rich bauxite deposits in the Ninayhin – Mpasaaso area, where geological reserves of approximately 300 million tons have been estimated. The project is part of the broader EU strategy to enhance access to critical raw materials and ensure strategic autonomy. Currently, feasibility studies for the development of the project are being conducted, which are expected to be completed by the end of 2025, after which decisions will be made on the next steps for development.
The “Healthcare Investment in Egypt” is being carried out with the participation of the “Athens Medical Group” and involves the provision of healthcare services at all levels. It is planned to create, either independently or in collaboration with the Government of Egypt, a wide network of diagnostic centers in Egypt to provide access to quality primary healthcare services to as many citizens as possible, covering the most strategic points in the country. Additionally, strategic investments are expected in the pharmaceutical industry, medical research and innovation, as well as the development of new protocols in collaboration with major medical technology companies and leading Medical Schools of the EU.